FR21C1044I2 - Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire - Google Patents

Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Info

Publication number
FR21C1044I2
FR21C1044I2 FR21C1044C FR21C1044C FR21C1044I2 FR 21C1044 I2 FR21C1044 I2 FR 21C1044I2 FR 21C1044 C FR21C1044 C FR 21C1044C FR 21C1044 C FR21C1044 C FR 21C1044C FR 21C1044 I2 FR21C1044 I2 FR 21C1044I2
Authority
FR
France
Prior art keywords
hao1
double
composition
stranded rna
specific inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1044C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of FR21C1044I1 publication Critical patent/FR21C1044I1/fr
Application granted granted Critical
Publication of FR21C1044I2 publication Critical patent/FR21C1044I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0006Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03015(S)-2-Hydroxy-acid oxidase (1.1.3.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR21C1044C 2013-12-27 2021-09-20 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire Active FR21C1044I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361921181P 2013-12-27 2013-12-27
US201461937838P 2014-02-10 2014-02-10
EP14874374.3A EP3087184B1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna
PCT/US2014/072410 WO2015100436A1 (en) 2013-12-27 2014-12-26 Methods and compositions for the specific inhibition of glycolate oxidase (hao1) by double-stranded rna

Publications (2)

Publication Number Publication Date
FR21C1044I1 FR21C1044I1 (ja) 2021-11-19
FR21C1044I2 true FR21C1044I2 (fr) 2022-09-23

Family

ID=53479713

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1044C Active FR21C1044I2 (fr) 2013-12-27 2021-09-20 Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire

Country Status (19)

Country Link
US (7) US9701966B2 (ja)
EP (3) EP3581654B1 (ja)
JP (2) JP6886818B2 (ja)
AU (2) AU2014369850B2 (ja)
CA (1) CA2935220A1 (ja)
CY (2) CY1124203T1 (ja)
DK (2) DK3087184T3 (ja)
ES (2) ES2749855T3 (ja)
FR (1) FR21C1044I2 (ja)
HR (1) HRP20210612T1 (ja)
HU (2) HUE055470T2 (ja)
LT (2) LT3581654T (ja)
LU (1) LUC00218I2 (ja)
NO (1) NO2021038I1 (ja)
PL (1) PL3581654T3 (ja)
PT (1) PT3581654T (ja)
RS (1) RS61892B1 (ja)
SI (1) SI3581654T1 (ja)
WO (1) WO2015100436A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
AU2014369850B2 (en) 2013-12-27 2021-04-08 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of Glycolate Oxidase (HAO1) by double-stranded RNA
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3310918B1 (en) * 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
JP2019531078A (ja) * 2016-10-05 2019-10-31 シンジェンタ パーティシペーションズ アーゲー リボ核酸の生物活性を保存する方法
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
CN112867795A (zh) * 2018-07-31 2021-05-28 因特利亚治疗公司 用于执行羟基酸氧化酶1(hao1)基因编辑以治疗1型原发性高草酸尿症(ph1)的组合物和方法
EP3898661A1 (en) * 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
AU2020376792A1 (en) 2019-11-01 2022-05-26 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
JP2023527525A (ja) * 2020-05-22 2023-06-29 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法
MX2023005496A (es) 2020-11-12 2023-08-04 Prec Biosciences Inc Meganucleasas manipuladas genéticamente que tienen especifidad para secuencias de reconocimiento en el gen de la distrofina.
EP4043018A1 (en) 2021-02-10 2022-08-17 Charité - Universitätsmedizin Berlin Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
WO2022256642A2 (en) * 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting hydroxyacid oxidase 1 (hao1) and uses thereof
TW202333748A (zh) * 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US513207A (en) 1894-01-23 Rail-brake
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
WO1992007065A1 (en) 1990-10-12 1992-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
DK0748382T3 (da) 1993-09-02 2003-02-17 Ribozyme Pharm Inc Enzymatisk nukleinsyre indeholdende ikke-nukleotid
US5889136A (en) 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US7678897B2 (en) * 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9879266B2 (en) * 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1742958B1 (en) 2004-03-15 2017-05-17 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
US8178503B2 (en) * 2006-03-03 2012-05-15 International Business Machines Corporation Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
JP4644619B2 (ja) 2006-03-27 2011-03-02 富士通株式会社 基地局装置、端末および帯域制御方法
DE102007021853A1 (de) 2007-05-10 2008-11-13 Norma Germany Gmbh Steckkupplung und Stutzen für eine Steckkupplung
US20110288147A1 (en) 2008-09-22 2011-11-24 Bob Dale Brown Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop
CN101752443B (zh) 2008-12-08 2012-06-20 鸿富锦精密工业(深圳)有限公司 光伏电池
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko) 2008-12-18 2017-04-19 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
EP2756845B1 (en) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
WO2010135682A1 (en) 2009-05-21 2010-11-25 Institute For Systems Biology New biomarkers for liver injury
WO2013075035A1 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
AU2014369850B2 (en) 2013-12-27 2021-04-08 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of Glycolate Oxidase (HAO1) by double-stranded RNA
JOP20200115A1 (ar) * 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))

Also Published As

Publication number Publication date
US20190211340A1 (en) 2019-07-11
EP3892727A1 (en) 2021-10-13
JP6886818B2 (ja) 2021-06-16
LUC00218I2 (ja) 2022-10-07
CY2021022I2 (el) 2021-12-31
NO2021038I1 (no) 2021-09-16
JP7109416B2 (ja) 2022-07-29
EP3581654A1 (en) 2019-12-18
PL3581654T3 (pl) 2021-09-13
EP3087184A4 (en) 2017-08-16
HUE055470T2 (hu) 2021-11-29
HRP20210612T1 (hr) 2021-08-20
US20200002705A1 (en) 2020-01-02
US9701966B2 (en) 2017-07-11
DK3087184T3 (da) 2019-07-29
FR21C1044I1 (ja) 2021-11-19
US9828606B2 (en) 2017-11-28
AU2014369850A1 (en) 2016-07-14
US11060093B2 (en) 2021-07-13
ES2875558T3 (es) 2021-11-10
LT3581654T (lt) 2021-06-25
US20170306333A1 (en) 2017-10-26
US10435692B2 (en) 2019-10-08
AU2021201953A1 (en) 2021-04-29
LTC3581654I2 (ja) 2023-07-10
EP3581654B1 (en) 2021-03-31
LTPA2021008I1 (ja) 2021-09-27
EP3087184B1 (en) 2019-07-03
US10465195B2 (en) 2019-11-05
AU2014369850B2 (en) 2021-04-08
SI3581654T1 (sl) 2021-08-31
CA2935220A1 (en) 2015-07-02
JP2020036603A (ja) 2020-03-12
CY1124203T1 (el) 2021-12-31
PT3581654T (pt) 2021-06-02
JP2017502668A (ja) 2017-01-26
US20180291379A1 (en) 2018-10-11
US20150184160A1 (en) 2015-07-02
US10487330B2 (en) 2019-11-26
US11873493B2 (en) 2024-01-16
HUS2100041I1 (hu) 2021-10-28
CY2021022I1 (el) 2021-12-31
EP3087184A1 (en) 2016-11-02
WO2015100436A1 (en) 2015-07-02
ES2749855T3 (es) 2020-03-24
DK3581654T3 (da) 2021-04-26
RS61892B1 (sr) 2021-06-30
US20190194665A1 (en) 2019-06-27
US20210230604A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
FR21C1044I2 (fr) Procédé et composition pour l'inhibition spécifique de la glycolate oxydase (hao1) par un arn bicaténaire
SMT201600274B (it) Processo per la preparazione di composti utili come inibitori del sglt2
IL240215A0 (en) Methods for the purification of messenger RNA
EP3134506A4 (en) Methods for purification of messenger rna
GB2511241B (en) Method for the removal of interfering metal ions using environmentally friendly competitive binders
GB2487632B (en) Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence
EP2895609A4 (en) METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
HK1227054A1 (zh) 利用雙鏈RNA以特異性抑制β-聯蛋白的方法和組成
EP3077511A4 (en) Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna
EP3087036A4 (en) Method for biological purification of water
FR2982259B1 (fr) Procede de production d'acrylate de 2-octyle par esterification directe
FR3039063B1 (fr) Procede d'enrichissement en pongamol d'huile de karanja
BR112014010997A2 (pt) processo para o preparo de ß-glicosídeos de c-arila
BR112014011620A2 (pt) processo de preparação de pelo menos uma nitrila
BR112014009775A2 (pt) composição, método, semente e composto de fórmula 1
FR2999572B1 (fr) Procede de production d'acrylate d'alkyle.
EP2931746A4 (en) METHOD AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRUCTURED RNA
EP3017042A4 (en) Method for the purification of targeted nucleic acids from background nucleic acids
FR3002771B1 (fr) Procede de production d'acrylate de 2-propyl heptyle par transesterefication
FR3040013B1 (fr) Procede de compactage d'une peinture anti-corrosion d'une piece de turbomachine
BR112014003169A2 (pt) processo de fundição de peças metálicas monocristalinas
BR112014008845A2 (pt) processo de tratamento anticorrosão
FR2985411B1 (fr) Procede pour favoriser l'exsudation de l'oleoresine et composition pour mettre en oeuvre ce procede
MX2014001409A (es) Metodo para tratar esquizofrenia.
FR2999175B1 (fr) Procede d'isolement de diamandoides